Education
About Us
Working with TipRanks
Follow Us
Biofrontera, Inc. (BFRI)
:BFRI
BFRI Stock Chart & Stats
$0.96
$0.09(8.11%)
At close: 4:00 PM EST
$0.96
$0.09(8.11%)
Day’s Range― - ―
52-Week Range$0.54 - $2.22
Previous CloseN/A
Volume12.39M
Average Volume (3M)101.58K
Market Cap
$10.24M
Enterprise Value$4.41M
Total Cash (Recent Filing)$7.24M
Total Debt (Recent Filing)$5.00M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Nov 30, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding10,668,442
10 Day Avg. Volume76,439
30 Day Avg. Volume101,578
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue0.11
Enterprise Value/Gross Profit0.18
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$6.00Price Target Upside525.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cost ReductionsThe move from transfer pricing to a royalty-based agreement and the resulting cost reductions will allow Biofrontera Inc. to reach breakeven more quickly.
Restructuring BenefitsThe re-negotiated agreement with Biofrontera AG will permit BFRI to gain further margin benefits going forward, with breakeven anticipated in 2026.
Bears Say
Tariff And Pricing UncertaintyPotential tariff and pricing uncertainty on pharmaceuticals are lessened but not eliminated following an announcement from Pfizer, as Biofrontera Inc. appears to fall under the current 15% tariff regime negotiated with the European Union.
Biofrontera News
BFRI FAQ
What was Biofrontera, Inc.’s price range in the past 12 months?
Biofrontera, Inc. lowest stock price was $0.54 and its highest was $2.22 in the past 12 months.
What is Biofrontera, Inc.’s market cap?
Biofrontera, Inc.’s market cap is $10.24M.
When is Biofrontera, Inc.’s upcoming earnings report date?
Biofrontera, Inc.’s upcoming earnings report date is Nov 30, 2025 which is in 42 days.
How were Biofrontera, Inc.’s earnings last quarter?
Biofrontera, Inc. released its earnings results on Aug 13, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.15.
Is Biofrontera, Inc. overvalued?
According to Wall Street analysts Biofrontera, Inc.’s price is currently Undervalued.
Does Biofrontera, Inc. pay dividends?
Biofrontera, Inc. does not currently pay dividends.
What is Biofrontera, Inc.’s EPS estimate?
Biofrontera, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Biofrontera, Inc. have?
Biofrontera, Inc. has 10,668,442 shares outstanding.
What happened to Biofrontera, Inc.’s price movement after its last earnings report?
Biofrontera, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went up 2.105%.
Which hedge fund is a major shareholder of Biofrontera, Inc.?
Currently, no hedge funds are holding shares in BFRI
Company Description
Biofrontera, Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Biofrontera's earnings call reflects a successful first half of 2025 marked by record sales, strategic independence, and strong financial backing, despite increased net losses and legal costs. The overall sentiment is buoyed by positive operational changes and future growth prospects.View all BFRI earnings summariesBFRI Stock 12 Month Forecast
Average Price Target
$6.00
▲(525.00% Upside)
Technical Analysis
China Pharma Holdings
―
Aytu BioScience
―
Shineco
―
Cosmos Holdings
―
Sunshine Biopharma
―
Ownership Overview
12.24% Insiders
0.46% Mutual Funds
18.49% Other Institutional Investors
68.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---